Another study of Botox for Migraines

July 6, 2007

Curtis Schreiber and Roger Cady reported their study at the recent annual meeting of the American Academy of Neurology. This was a randomized, double-blind, placebo controlled study Another study of Botox for migraines. Curtis Schreiber and Roger Cady reported their study at the recent annual meeting of the American Academy of Neurology. This was a randomized, double-blind, placebo controlled study (that is the most reliable kind of a study) of patients who had disabling headaches and had difficulty complying with their previous prophylactic treatment. 60 received Botox and 21 received placebo injections. There was a significant improvement in headache frequency, headache impact (so called HIT-6 measure) and treatment satisfaction in patients who received Botox compared to those who received placebo. There are about 100 published reports on the use of Botox for migraine headaches and the experience of most headache experts in the US is very positive. However, many insurance companies will not cover Botox because the FDA has not yet approved it for migraines. Allergan, the company that manufactures Botox is conducting the FDA-required trials (we at NYHC are participating in one of the two trials), but the earliest possible time for approval is 2009.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe